Hormone Receptor Positive HER-2 Negative Breast Cancer Clinical Trials
3 recruiting
Showing 1–4 of 4 trials
Recruiting
Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer
Hormone Receptor Positive HER-2 Negative Breast Cancer
University Hospital Tuebingen504 enrolled1 locationNCT05878314
Recruiting
Phase 2
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Metastatic Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerRecurrent Breast Cancer
Puma Biotechnology, Inc.150 enrolled53 locationsNCT06369285
Recruiting
Phase 2
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
Advanced or Metastatic Breast CancerBRCA1 MutationBRCA2 Mutation+1 more
GBG Forschungs GmbH176 enrolled36 locationsNCT06201234
Recruiting
Phase 3
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Hormone Receptor Positive HER-2 Negative Breast Cancer
Fudan University1,736 enrolled1 locationNCT05901428